This page shows you your search results in order of relevance. This is page number 15.
Order by Relevance | Date
Total 817380 results found since Jan 2013.
Merck ’s KEYTRUDA® (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1
Dateline City:
KENILWORTH, N.J. KEYNOTE-010 Published in The Lancet and to be Presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced results from the pivotal KEYNOTE-010 study, the first
study of its kind to evaluate the potential of an immunotherapy compared
to chemotherapy based on prospective measurement of PD-L1 expression in
patients with advanced non-small cell lung cancer (NSCLC). Language:
English Contact: Merc...
Source: Merck.com - Product News - December 19, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda Melanoma MSD pembrolizumab Source Type: news
FDA Approves Expanded Indication for Merck ’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma
Dateline City:
KENILWORTH, N.J. KEYTRUDA is Now the First and Only Anti-PD-1 Therapy to Achieve Superior Overall Survival Compared to Ipilimumab KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved an expanded indication for KEYTRUDA ® (pembrolizumab),
the company ’s anti-PD-1 (programmed death receptor-1) therapy, to
include the first-line treatment of patients with unresectable or
metastatic melanoma. Language:
English Contact: ...
Source: Merck.com - Product News - December 18, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda Melanoma MSD NYSE:MRK Source Type: news
Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA ® (pembrolizumab) in Advanced Colorectal Cancer
Dateline City:
KENILWORTH, N.J. Designation Based on Results in Patients with Metastatic Colorectal Cancer with High Levels of Microsatellite Instability KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
granted Breakthrough Therapy Designation to KEYTRUDA ®
(pembrolizumab), the company ’s anti-PD-1 therapy, for the treatment of
patients with microsatellite instability high (MSI-H) metastatic
colorectal cancer. This is the third Breakthrough Therapy De...
Source: Merck.com - Product News - November 2, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #cancer #Merck #MRK $MRK colorectal cancer Keytruda MSD NYSE:MRK Source Type: news
Merck ’s KEYTRUDA® (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1
Dateline City:
KENILWORTH, N.J. Merck Plans Regulatory Submissions in the U.S. in late 2015 and in the European Union in Early 2016 KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced topline results from the KEYNOTE-010 study of KEYTRUDA ®
(pembrolizumab) in advanced non-small-cell lung cancer (NSCLC)
demonstrating that the trial met its primary objective. Language:
English Contact: Merck Media: Pamela Eisele, 267-305-3558 Courtney Ronaldo, 908-236-1108 or Investors: Teri Loxam, 908-740-19...
Source: Merck.com - Product News - October 26, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
FDA Approves KEYTRUDA ® (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy
Dateline City:
KENILWORTH, N.J. Patients with EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression on FDA-Approved Therapy for These Aberrations Prior to Receiving KEYTRUDA KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved KEYTRUDA ® (pembrolizumab) monotherapy, the company ’s
anti-PD-1 (programmed death receptor-1) therapy, at a dose of 2 mg/kg
every three weeks, for the treatment of patients with metastatic
non-small cell l...
Source: Merck.com - Product News - October 2, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
MARIZEV ® (Omarigliptin), Merck’s Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes, Approved in Japan
Dateline City:
KENILWORTH, N.J. KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Japanese Pharmaceuticals and Medical Devices
Agency (PMDA) has approved MARIZEV ® (omarigliptin) 25 mg and
12.5 mg tablets, an oral, once-weekly DPP-4 inhibitor indicated for the
treatment of adults with type 2 diabetes. Japan is the first country to
have approved omarigliptin. Language:
English Contact: Media Contacts: Pam Eisele, 267-305-3558 or Michael Close, 310-617-1067 or Kristen Drake, 908-236-4223...
Source: Merck.com - Product News - September 28, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
New Data from KEYNOTE-028, Merck ’s Trial Evaluating KEYTRUDA® (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress
Dateline City:
KENILWORTH, N.J. Findings Show Anti-Tumor Activity for KEYTRUDA in Two Gastrointestinal Cancers KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced new findings from the KEYNOTE-028 Phase 1b study, the
clinical trial investigating the use of the company ’s anti-PD-1 therapy,
KEYTRUDA ® (pembrolizumab) in multiple, difficult-to-treat
cancers. Data from this trial, to be presented at the European Cancer
Congress (ECC) in Vienna, Austria, Sept. Language:
English Contact: Merc...
Source: Merck.com - Product News - September 27, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
Data in Nine Difficult-to-Treat Cancers from Merck ’s KEYTRUDA® (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ...
Dateline City:
KENILWORTH, N.J. ...Nasopharyngeal Carcinoma, Anal Cancer, Merkel Cell Carcinoma and Biliary Tract Cancer Data to Include First-Time Findings on the Potential Importance of PD-L2 Expression in Predicting Patient Responsiveness to Anti-PD-1 Therapy KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that new data investigating the anti-tumor activity of
KEYTRUDA ® (pembrolizumab) across a broad range of advanced
cancers will be presented at this year ’s European Cancer Congress (ECC)
in ...
Source: Merck.com - Product News - September 21, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
Merck and Samsung Bioepis Announce Approval of BRENZYS ™ (Etanercept), a Biosimilar of Enbrel, in Korea
Dateline City:
KENILWORTH, N.J. & SEOUL, South Korea First Product from Global Partnership to Deliver High-Quality Biosimilars to Help Meet Needs of Patients and Healthcare Systems Worldwide KENILWORTH, N.J. & SEOUL, South Korea--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Samsung Bioepis Co., Ltd. today announced the approval of BRENZYS ™
(etanercept), a biosimilar of the immunology medicine Enbrel, by the
Ministry of Food and Drug Safety (MFDS) in Korea. Language:
English Contact: Merck Media: Pamela Eisele, 267-3...
Source: Merck.com - Product News - September 8, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Results of Phase 2 Study of Merck ’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
Dateline City:
KENILWORTH, N.J. Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial Infections KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that a Phase 2 study of relebactam, the company ’s
investigational beta-lactamase inhibitor, in combination with
imipenem/cilastatin (an approved carbapenem antibiotic), in patients
with complicated urinary tract infections, met its primary endpoint. Language:
English Contact: Merck Media: Pamela Eisele, (267) 305-3558 or Robert Con...
Source: Merck.com - Research and Development News - June 20, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ASM MSD NYSE:MRK Source Type: news
Merck ’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus®
Dateline City:
KENILWORTH, N.J. Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced results from two Phase 3 studies evaluating MK-1293,
Merck ’s investigational, follow-on biologic* insulin glargine candidate
for the treatment of people with type 1 and type 2 diabetes. Language:
English Contact: Merck Media: Doris Li, 908-246-5701 Kristen Dra...
Source: Merck.com - Research and Development News - June 13, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK MSD Source Type: news
New Data from Phase 2 Study Evaluating KEYTRUDA ® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers
Dateline City:
KENILWORTH, N.J. KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced updated findings from a study evaluating KEYTRUDA ®
(pembrolizumab), the company ’s anti-PD-1 therapy, in patients with
advanced cancers characterized as deficient for DNA mismatch repair
(MMR). Language:
English Contact: Merck Media: Pamela Eisele, 267-305-3558 Kim Hamilton, 908-740-1863 or Investors: Teri Loxam, 908-740-1986 Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Research and Development News - June 5, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO Keytruda MSD Source Type: news
New KEYTRUDA ® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting
Dateline City:
KENILWORTH, N.J. Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up KEYNOTE-001 Findings Show Continued Benefit in Response Rates, Duration of Response, and Include New Three-Year Overall Survival Data for KEYTRUDA KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced final overall survival (OS) data from KEYNOTE-006 and
new findin...
Source: Merck.com - Research and Development News - May 18, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
Merck ’s Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study
Dateline City:
KENILWORTH, N.J. Results to be Presented at Future Medical Meeting, and Regulatory Submissions Planned for 2016 KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced top-line results from the company ’s Phase 3 pivotal
trial, ONCEMRK. ONCEMRK is evaluating an investigational once-daily
formulation of ISENTRESS ® (raltegravir), known as
raltegravir 600 mg (to be given as 2 x 600 mg once-daily), for
previously untreated HIV-1 infected adults. Language:
English Contact: For Mer...
Source: Merck.com - Research and Development News - February 22, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ISENTRESS NYSE:MRK Source Type: news
Systematic Review of 58 Publications of Real-World Use of GARDASIL ® Presented at EUROGIN Congress
Dateline City:
KENILWORTH, N.J. Studies Published over the Last 10 Years Report Reductions in Cervical Pre-cancers and Other HPV-related Diseases KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
announced today that in a systematic review conducted of the global
impact and effectiveness of GARDASIL ® [Human Papillomavirus
Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], substantial
reductions were observed in HPV 6/11/16/18-related infection, genital
warts, Pap abnormalities and cervical pre-cancers. Langu...
Source: Merck.com - Corporate News - June 16, 2016 Category: Pharmaceuticals Tags: Vaccine News Corporate News Latest News #Merck #MRK $MRK EUROGIN Gardasil MSD NYSE:MRK Source Type: news
